Loxo Oncology Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 96
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $6.92B
Latest Deal Amount

Loxo Oncology General Information

Description

Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Parent Company
Primary Office
  • 281 Tresser Boulevard
  • 9th Floor
  • Stamford, CT 06901
  • United States
+1 (203) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Loxo Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 15-Feb-2019 $6.92B 00000 00.000 Completed Generating Revenue
9. Secondary Transaction - Open Market 31-Mar-2018 00000 Completed Clinical Trials - Phase 1
8. Secondary Transaction - Open Market 31-Mar-2017 00000 Completed Clinical Trials - Phase 1
7. PIPE 05-Jan-2017 00.000 00000 00000 Completed Clinical Trials - Phase 1
6. Secondary Transaction - Open Market 31-Mar-2016 00000 Completed Clinical Trials - Phase 1
5. 2PO 17-Nov-2015 000.00 00000 Completed Clinical Trials - Phase 1
4. IPO 01-Aug-2014 000.00 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 06-May-2014 000.00 000.00 00000 Completed Generating Revenue/Not Profitable
2. Early Stage VC (Series A) 03-Oct-2013 $33M $33M 000.00 Completed Generating Revenue/Not Profitable
1. Early Stage VC Completed Generating Revenue/Not Profitable
To view Loxo Oncology’s complete valuation and funding history, request access »

Loxo Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.00
Series A1 000,000 00.000000 00 000 000.00 00 000 0.000
Series A 3,300,000 $0.000100 8% $10 $10 44.13%
To view Loxo Oncology’s complete cap table history, request access »

Loxo Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increas
Pharmaceuticals
Stamford, CT
96 As of 2018
00000
0.000 0000-00-00
000000&0 00000

0000 000

a. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Houston, TX
00 As of 0000
00000
000 0000-00-00
000000&0 00000

000 0000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000 000000000
Cambridge, MA
000 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Loxo Oncology Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kuur Therapeutics Formerly VC-backed Houston, TX 00 00000 000000&0 00000
000 00000000(00000 Corporation Cambridge, MA 000 000.00 00000000 000.00
00000000 000000000 Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
0000000 0000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000&0 00000
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
You’re viewing 5 of 44 competitors. Get the full list »

Loxo Oncology Executive Team (22)

Name Title Board Seat Contact Info
Jacob Naarden Chief Executive Officer
Nisha Nanda Ph.D Chief Development Officer
Sara Slifka Vice President, Business Operations and Program Management
Deborah Morosini MD Vice President, Clinical Affairs and Patient Engagement
Christopher Pierce Vice President, Commercial
You’re viewing 5 of 22 executive team members. Get the full list »

Loxo Oncology Board Members (8)

Name Representing Role Since
Avi Naider Self Chairman, Audit Committee & Board of Directors 000 0000
David Bonita MD OrbiMed Board Member 000 0000
Lori Kunkel MD Loxo Oncology Board Member 000 0000
Timothy Mayleben Self Board Member 000 0000
You’re viewing 4 of 8 board members. Get the full list »

Loxo Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Loxo Oncology Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Array BioPharma Corporation Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Loxo Oncology Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000000 (000 0 28-Jul-2017 000000000 00000 00 0000 Buildings and Property 00000 0000000
To view Loxo Oncology’s complete investments history, request access »